Advertisement

World Journal of Surgery

, Volume 33, Issue 10, pp 2112–2118 | Cite as

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

  • Xiu Li Zhang
  • Yun Sheng Yang
  • Dong Ping Xu
  • Jian Hui Qu
  • Ming Zhou Guo
  • Yan Gong
  • Jin Huang
Article

Abstract

Background

Owing to the special importance of the HER family in tumorigenesis, the downstream signaling pathways and effectors have become the key molecules in the strategy of carcinoma-targeted therapy. Recent evidence that HER3 is responsible for tumor resistance to therapeutic agents targeting EGFR or HER2/neu, along with the new findings that HER3 is involved in the process of dedifferentiation of gastric cancer (GC) have highlighted the critical role of HER3 in cancer research. HER3 is becoming a new targeted molecule in cancer treatment. Here, we comparatively investigated the expression of HER2/neu and HER3 in gastric cancer of two pathologic types (intestinal type and diffuse type) using immunohistochemistry (IHC) and analyzed the correlation between overexpression of HER2 and HER3 and clinicopathologic parameters.

Methods

An IHC study for HER2 and HER3 was performed on 102 formalin-fixed, paraffin-embedded specimens of GC—60 intestinal and 42 diffuse types. The correlation between overexpression of HER2 and HER3 and clinicopathologic parameters was statistically analyzed.

Results

In the GC group, overexpression of HER2 and HER3 was detected in 19 (18.6%) and 14 (13.7%) of 102 GC patients, respectively. In a nontumorous group of 102 specimens, 5 were HER2-positive (4.9%) (18.6% vs. 4.9%, p < 0.01), and 2 were HER3-positive (2.0%) (13.7% vs. 2.0%, p < 0.01). No co-overexpression of HER2 and HER3 was observed. The intestinal type of GC exhibited a higher rate of HER2 overexpression than did the diffuse type (26.7% vs. 7.1%, p < 0.05), whereas the diffuse type of GC exhibited a significantly higher rate of HER3 overexpression than did the intestinal type (26.2% vs. 5.0%, p < 0.01). The overexpression rates of HER2 and HER3 in phase III–IV (TNM stage) disease were significantly higher than that in phase I–II disease (24.0% vs. 7.7%, p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). HER2 and HER3 overexpression was also correlated with a significantly worse survival (p = 0.046 and 0.024, respectively).

Conclusions

The selective overexpression of HER2 and HER3 in the two histologic types of gastric cancer is strongly associated with a poor prognosis. Being an important member of the HER family, HER3 may become another candidate for molecular-targeted therapy in gastric cancer, especially for the diffuse histologic type.

Keywords

Gastric Cancer Epidermal Growth Factor Receptor Human Epidermal Growth Factor Receptor Gastric Cancer Tissue Herceptin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bulanov D (2007) Gastric cancer-current state of the problem. Part I. Epidemiology, pathology, classification, staging. Khirurgiia (Sofiia) 4:48–59Google Scholar
  2. 2.
    Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer 5:5–11PubMedCrossRefGoogle Scholar
  3. 3.
    Ahmed KM, Cao N, Li JJ (2006) HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 26:4235–4243PubMedGoogle Scholar
  4. 4.
    Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485–498PubMedCrossRefGoogle Scholar
  5. 5.
    Derin D, Eralp Y, Ozluk Y et al (2008) Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest 26:671–679PubMedCrossRefGoogle Scholar
  6. 6.
    Burris H, Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289–298PubMedCrossRefGoogle Scholar
  7. 7.
    Duneau JP, Vegh AP, Sturgis JN (2007) A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 46:2010–2019PubMedCrossRefGoogle Scholar
  8. 8.
    Zaczek A, Brandt B, Bielawski KP (2005) The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20:1005–1015PubMedGoogle Scholar
  9. 9.
    Yokoyama H, Ikehara Y, Kodera Y et al (2006) Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 95:1504–1513PubMedCrossRefGoogle Scholar
  10. 10.
    Pratilas CA, Hanrahan AJ, Halilovic E et al (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375–9383PubMedCrossRefGoogle Scholar
  11. 11.
    Lesma E, Grande V, Ancona S et al (2008) Anti-EGFR antibody efficiently and specifically inhibits human TSC2/ smooth muscle cell proliferation: possible treatment options for TSC and LAM. PLoS ONE 3:e3558PubMedCrossRefGoogle Scholar
  12. 12.
    Hirata A, Hosoi F, Miyagawa M et al (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253–4260PubMedCrossRefGoogle Scholar
  13. 13.
    Graeff P, Crijns AP, Ten Hoor KA et al (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99:341–349PubMedCrossRefGoogle Scholar
  14. 14.
    Rusnak DW, Lackey K, Affleck K et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85–94PubMedGoogle Scholar
  15. 15.
    Kim SY, Kim HP, Kim YJ et al (2008) Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32:89–95PubMedGoogle Scholar
  16. 16.
    Inui T, Asakawa A, Morita Y et al (2006) HER-2overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 260:484–487PubMedCrossRefGoogle Scholar
  17. 17.
    Srinivasan R, Leverton KE, Sheldon H et al (2001) Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. Cell Signal 13:321–330PubMedCrossRefGoogle Scholar
  18. 18.
    Kim KK, Lee JJ, Yang Y et al (2008) Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704–712PubMedCrossRefGoogle Scholar
  19. 19.
    Akiyama T, Sudo C, Ogawara H (1986) The product of the human c-erbB–2 gene: a 185-kilo-dalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646PubMedCrossRefGoogle Scholar
  20. 20.
    Sakai K, Mori S, Kawamoto T et al (1986) Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77:1047–1052PubMedGoogle Scholar
  21. 21.
    Tokunaga A, Onda M, Okuda T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75:1418–1425PubMedCrossRefGoogle Scholar
  22. 22.
    Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65–71PubMedGoogle Scholar
  23. 23.
    Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413–448PubMedCrossRefGoogle Scholar
  24. 24.
    Hayashi M, Inokuchi M, Takagi Y et al (2008) High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14:7843–7849PubMedCrossRefGoogle Scholar
  25. 25.
    Katoh M, Yazaki Y, Sugimura T et al (1993) c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem Biophys Res Commun 192:1189–1197PubMedCrossRefGoogle Scholar
  26. 26.
    Lordick F, Bang YJ, Kang YK (2007) HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 5:271Google Scholar
  27. 27.
    Cooperative Study Group of HER2 in China (2006) Multicenter study on HER-2/new gene amplification and protein expression in patients with gastric cancer. Chin J Dig 26:657–660Google Scholar
  28. 28.
    Michimoto K, Akihiro I, Azusa SK et al (2003) Activation of ErbB3–PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 22:1294–1301CrossRefGoogle Scholar
  29. 29.
    Sanidas EE, Filipe MI, Linehan J et al (1993) Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer 54:935–940PubMedCrossRefGoogle Scholar
  30. 30.
    Yamashita K, Sakuramoto S, Kikuchi S et al (2008) Validation of staging systems for gastric cancer. Gastric Cancer 11:111–118PubMedCrossRefGoogle Scholar
  31. 31.
    Tateishi M, Toda T, Minamisono Y et al (1992) Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 49:209–212CrossRefGoogle Scholar
  32. 32.
    Sasano H, Date F, Imatani A et al (1993) Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584–589PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia I, Vizoso F, Martin A et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234–241PubMedCrossRefGoogle Scholar
  34. 34.
    Okegawa T, Kinjo M, Nutahara K et al (2006) Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 13:1197–1201PubMedCrossRefGoogle Scholar
  35. 35.
    Kapitanović S, Radosević S, Slade N et al (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126:205–211PubMedCrossRefGoogle Scholar
  36. 36.
    Reschke M, Mihic-Probst D, van der Horst EH et al (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14:5188–5197PubMedCrossRefGoogle Scholar
  37. 37.
    Lee HST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878–5887CrossRefGoogle Scholar
  38. 38.
    Narayan M, Wilken JA, Harris LN et al (2009) Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 69:2191–2194PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2009

Authors and Affiliations

  • Xiu Li Zhang
    • 1
  • Yun Sheng Yang
    • 1
  • Dong Ping Xu
    • 2
  • Jian Hui Qu
    • 2
  • Ming Zhou Guo
    • 1
  • Yan Gong
    • 1
  • Jin Huang
    • 1
  1. 1.Department of Gastroenterology and HepatologyChinese PLA General HospitalBeijingChina
  2. 2.Laboratory of Gene Therapy302 Hospital of Chinese PLABeijingChina

Personalised recommendations